<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880475</url>
  </required_header>
  <id_info>
    <org_study_id>OXN08-CN-101</org_study_id>
    <nct_id>NCT02880475</nct_id>
  </id_info>
  <brief_title>OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, Parallel Group Study to Investigate the Pharmacokinetics of Oxycodone and Naloxone From OXN 5/2.5 and OXN 20/10 in Chinese Patients With Moderate to Severe Chronic Non-malignant Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma (China) Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma (China) Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, single-dose, parallel group study. The objectives of this
      study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN)
      prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10 mg (OXN 20/10) in Chinese
      patients with moderate to severe chronic non-malignant pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be conducted to assess the pharmacokinetics of OXN 5/2.5 and OXN 20/10 tablets.
      Subjects will be allocated to a sequence of two strength group in accordance with a random
      allocation schedule (RAS) in a 1:1 ratio.

      Subjects will attend a screening visit within 14 days of the first (OXN) dosing day (Day 1).

      Eligible subjects will then check into the study unit on the day before OXN dosing (Day -2).
      Subjects will be administered their OXN dose the next 2 morning (Day 1), following an
      overnight fast.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Actual">July 10, 2015</completion_date>
  <primary_completion_date type="Actual">June 1, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-48hr of Noroxycodone Plasma Concentration.</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Noroxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Noroxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Oxycodone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Oxymorphone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of 6-B-Naloxol Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of NLLG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of NLXG Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-48hr of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC_%Extrap of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lambda_z of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of Naloxone Plasma Concentration</measure>
    <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
    <description>Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>OXN prolonged release tablet 5/2.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXN prolonged release tablet 20/10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXN PR tablet</intervention_name>
    <description>Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
    <arm_group_label>OXN prolonged release tablet 20/10mg</arm_group_label>
    <arm_group_label>OXN prolonged release tablet 5/2.5mg</arm_group_label>
    <other_name>Targin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult Chinese patients with moderate to severe chronic non-malignant pain.

          2. Male and female subjects with age range 18 to 65 years (including 18 and 65), body
             weight ≥ 45kg and BMI range 18 to 30 (including 18 and 30).

          3. Patients who should rate their pain (Pain Intensity Scale -&quot;average pain&quot; over the
             last 24 hours) as ≥4 on 0-10 scale.

          4. Patients, who are able to read, understand and sign written informed consent prior to
             study participation and are willing to follow the protocol requirements.

          5. Females of childbearing potential and less than one year post-menopausal must have a
             negative serum pregnancy test during screening visit and at check-in and be
             non-lactating. In addition, they must be willing to use adequate and reliable
             contraception throughout the study. Highly effective methods of birth control are
             defined as those which result in a low failure rate (i.e. less than 1% per year) when
             used consistently and correctly such as sterilization, implants, injectables, combined
             oral contraceptives, some IUDs (intrauterine Device, hormonal), sexual abstinence or
             vasectomised partner.

        Exclusion Criteria:

          1. Females who are pregnant (positive β-human chorionic gonadotrophin [HCG] test) or
             lactating.

          2. Use of opioid or opioid antagonist-containing medication in the 30 days before the
             start of the study.

          3. Known sensitivity to oxycodone, naloxone, or related compounds.

          4. Subjects with clinically unstable respiratory disease, dysfunction of the biliary
             tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy
             requiring intervention (medication or surgical) or renal artery stenosis, or any other
             medical condition, that, in the opinion of the investigator or the sub-investigator,
             precludes entry into this study.

          5. Subject who have a past (within 5 years) history of malignant neoplasm including
             leukemia and lymphoma.

          6. The electrocardiogram examination results are abnormal, in the opinion of the
             investigator or the sub-investigator, and are clinical significance.

          7. Subjects with abnormal liver function (values exceed the upper limit of normal for
             AST, ALT or total bilirubin during the Screening Period) or abnormal renal function
             (values exceed the upper limit of normal for serum creatinine during the Screening
             Period).

          8. Patients with a contraindication to the study medication.

          9. Subjects who have a psychiatric disorder such that participation in the study may, in
             the opinion of the investigator or the sub-investigator, pose an unacceptable risk to
             the subject.

         10. Subjects who have a current or past (within 5 years) history of substance or alcohol
             abuse, or subjects who give a positive result in drug abuse test during the Screening
             Period, or subjects who, in the opinion of the investigator or the sub-investigator,
             have demonstrated addictive or substance abuse behaviors.

         11. Subjects with uncontrolled seizures or convulsive disorder.

         12. Subjects who will receive any interventional therapy (surgery, paracentesis,etc) for
             arthritis during the study period.

         13. History of or any current conditions that might have interfered with drug absorption,
             distribution, metabolism or excretion.

         14. Any history of frequent nausea or emesis regardless of aetiology.

         15. Participation in any clinical drug study during the 3 months preceding the initial
             dose in this study.

         16. Use of any medication including vitamins, herbal and/or mineral supplements during the
             course of the study, other than Vitamin D, calcium supplements and continued use by
             females of contraceptive medication or HRT.

         17. Consumption of alcoholic beverages within 48 hours before study drug administration,
             and refusal to abstain from alcohol until at least 48 hours after the last study drug
             administration.

         18. Blood or blood products donated within 90 days prior to study drug administration or
             anytime during the study, except as required by this protocol.

         19. Positive results of urine drug screen(for opioids, barbiturates, amphetamines, cocaine
             metabolites, methadone, diazepam and cannabinoids), alcohol breath test, hepatitis B
             surface antigen (HBsAg), hepatitis C virus antibody (Ab), human immunodeficiency virus
             (HIV) test or qualitative syphilis tests.

         20. Patients with moderate to severe hypohemia (HGB&lt;90g/L during the screening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria YU</last_name>
    <role>Study Director</role>
    <affiliation>Mundipharma (China) Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <results_first_submitted>March 5, 2018</results_first_submitted>
  <results_first_submitted_qc>April 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2019</results_first_posted>
  <last_update_submitted>April 28, 2019</last_update_submitted>
  <last_update_submitted_qc>April 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe chronic non-malignant pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 25, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02880475/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02880475/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OXN Prolonged Release Tablet 5/2.5 mg</title>
          <description>The subjects were randomized to receive a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg</description>
        </group>
        <group group_id="P2">
          <title>OXN Prolonged Release Tablet 20/10 mg</title>
          <description>The subjects were randomized to receive a single dose of OXN prolonged release tablets 20/10mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 20/10 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OXN PR Tablet 5/2.5 mg</title>
          <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
        </group>
        <group group_id="B2">
          <title>OXN PR Tablet 20/10 mg</title>
          <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of Noroxycodone Plasma Concentration.</title>
        <description>AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.</time_frame>
        <population>12 subjects in OXN PR tablet 5/2.5 mg group,12 subjects in OXN PR tablet 20/10 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN PR Tablet 5/2.5 mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN PR Tablet 20/10 mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of Noroxycodone Plasma Concentration.</title>
          <description>AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.</description>
          <population>12 subjects in OXN PR tablet 5/2.5 mg group,12 subjects in OXN PR tablet 20/10 mg group.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.72" spread="39.82"/>
                    <measurement group_id="O2" value="325.51" spread="99.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Noroxycodone Plasma Concentration</title>
        <description>AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.</time_frame>
        <population>12 subjects in OXN PR tablet 5/2.5 mg group,12 subjects in OXN PR tablet 20/10 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Noroxycodone Plasma Concentration</title>
          <description>AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )</description>
          <population>12 subjects in OXN PR tablet 5/2.5 mg group,12 subjects in OXN PR tablet 20/10 mg group.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.25" spread="40.27"/>
                    <measurement group_id="O2" value="325.37" spread="99.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of Noroxycodone Plasma Concentration</title>
        <description>AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of Noroxycodone Plasma Concentration</title>
          <description>AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="1.17"/>
                    <measurement group_id="O2" value="1.45" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of Noroxycodone Plasma Concentration</title>
        <description>AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of Noroxycodone Plasma Concentration</title>
          <description>AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.74" spread="41.66"/>
                    <measurement group_id="O2" value="330.44" spread="102.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Noroxycodone Plasma Concentration</title>
        <description>Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Noroxycodone Plasma Concentration</title>
          <description>Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="1.53"/>
                    <measurement group_id="O2" value="20.69" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of Noroxycodone Plasma Concentration</title>
        <description>Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of Noroxycodone Plasma Concentration</title>
          <description>Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.02"/>
                    <measurement group_id="O2" value="0.10" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of Noroxycodone Plasma Concentration</title>
        <description>T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Noroxycodone Plasma Concentration</title>
          <description>T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="1.42"/>
                    <measurement group_id="O2" value="7.16" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Noroxycodone Plasma Concentration</title>
        <description>Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Noroxycodone Plasma Concentration</title>
          <description>Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="1.50" upper_limit="8.02"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.50" upper_limit="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of Noroxymorphone Plasma Concentration</title>
        <description>AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of Noroxymorphone Plasma Concentration</title>
          <description>AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.10" spread="5.02"/>
                    <measurement group_id="O2" value="65.84" spread="25.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Noroxymorphone Plasma Concentration</title>
        <description>AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Noroxymorphone Plasma Concentration</title>
          <description>AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.92" spread="5.21"/>
                    <measurement group_id="O2" value="65.65" spread="25.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of Noroxymorphone Plasma Concentration</title>
        <description>AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of Noroxymorphone Plasma Concentration</title>
          <description>AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.89" spread="11.61"/>
                    <measurement group_id="O2" value="4.25" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of Noroxymorphone Plasma Concentration</title>
        <description>AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of Noroxymorphone Plasma Concentration</title>
          <description>AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.76" spread="4.68"/>
                    <measurement group_id="O2" value="68.17" spread="26.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Noroxymorphone Plasma Concentration</title>
        <description>Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Noroxymorphone Plasma Concentration</title>
          <description>Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.29"/>
                    <measurement group_id="O2" value="3.54" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of Noroxymorphone Plasma Concentration</title>
        <description>Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of Noroxymorphone Plasma Concentration</title>
          <description>Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.02"/>
                    <measurement group_id="O2" value="0.08" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of Noroxymorphone Plasma Concentration</title>
        <description>T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Noroxymorphone Plasma Concentration</title>
          <description>T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" spread="1.53"/>
                    <measurement group_id="O2" value="9.08" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Noroxymorphone Plasma Concentration</title>
        <description>Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Noroxymorphone Plasma Concentration</title>
          <description>Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="2.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="2.50" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of Oxycodone Plasma Concentration</title>
        <description>AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of Oxycodone Plasma Concentration</title>
          <description>AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.48" spread="34.38"/>
                    <measurement group_id="O2" value="272.11" spread="48.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Oxycodone Plasma Concentration</title>
        <description>AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Oxycodone Plasma Concentration</title>
          <description>AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.45" spread="34.55"/>
                    <measurement group_id="O2" value="271.21" spread="48.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of Oxycodone Plasma Concentration</title>
        <description>AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of Oxycodone Plasma Concentration</title>
          <description>AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="1.15"/>
                    <measurement group_id="O2" value="0.57" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of Oxycodone Plasma Concentration</title>
        <description>AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of Oxycodone Plasma Concentration</title>
          <description>AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.85" spread="34.72"/>
                    <measurement group_id="O2" value="272.71" spread="48.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Oxycodone Plasma Concentration</title>
        <description>Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Oxycodone Plasma Concentration</title>
          <description>Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="1.67"/>
                    <measurement group_id="O2" value="24.64" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of Oxycodone Plasma Concentration</title>
        <description>Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of Oxycodone Plasma Concentration</title>
          <description>Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.04"/>
                    <measurement group_id="O2" value="0.14" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of Oxycodone Plasma Concentration</title>
        <description>T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Oxycodone Plasma Concentration</title>
          <description>T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="0.96"/>
                    <measurement group_id="O2" value="5.03" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Oxycodone Plasma Concentration</title>
        <description>Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Oxycodone Plasma Concentration</title>
          <description>Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" lower_limit="1.02" upper_limit="8.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of Oxymorphone Plasma Concentration</title>
        <description>AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of Oxymorphone Plasma Concentration</title>
          <description>AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="1.33"/>
                    <measurement group_id="O2" value="3.59" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Oxymorphone Plasma Concentration</title>
        <description>AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Oxymorphone Plasma Concentration</title>
          <description>AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.33"/>
                    <measurement group_id="O2" value="1.66" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of Oxymorphone Plasma Concentration</title>
        <description>AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of Oxymorphone Plasma Concentration</title>
          <description>AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.85" spread="21.51"/>
                    <measurement group_id="O2" value="51.11" spread="26.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of Oxymorphone Plasma Concentration</title>
        <description>AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of Oxymorphone Plasma Concentration</title>
          <description>AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Oxymorphone Plasma Concentration</title>
        <description>Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Oxymorphone Plasma Concentration</title>
          <description>Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.06"/>
                    <measurement group_id="O2" value="0.30" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of Oxymorphone Plasma Concentration</title>
        <description>Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of Oxymorphone Plasma Concentration</title>
          <description>Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of Oxymorphone Plasma Concentration</title>
        <description>T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Oxymorphone Plasma Concentration</title>
          <description>T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Oxymorphone Plasma Concentration</title>
        <description>Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Oxymorphone Plasma Concentration</title>
          <description>Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.75" lower_limit="0.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of 6-B-Naloxol Plasma Concentration</title>
        <description>AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of 6-B-Naloxol Plasma Concentration</title>
          <description>AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1655.48" spread="667.02"/>
                    <measurement group_id="O2" value="5065.33" spread="3358.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of 6-B-Naloxol Plasma Concentration</title>
        <description>AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of 6-B-Naloxol Plasma Concentration</title>
          <description>AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1373.11" spread="779.63"/>
                    <measurement group_id="O2" value="5049.62" spread="3374.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of 6-B-Naloxol Plasma Concentration</title>
        <description>AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of 6-B-Naloxol Plasma Concentration</title>
          <description>AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.24" spread="15.98"/>
                    <measurement group_id="O2" value="33.37" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of 6-B-Naloxol Plasma Concentration</title>
        <description>AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of 6-B-Naloxol Plasma Concentration</title>
          <description>AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1828.39" spread="878.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of 6-B-Naloxol Plasma Concentration</title>
        <description>Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of 6-B-Naloxol Plasma Concentration</title>
          <description>Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.18" spread="47.25"/>
                    <measurement group_id="O2" value="269.53" spread="189.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of 6-B-Naloxol Plasma Concentration</title>
        <description>Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of 6-B-Naloxol Plasma Concentration</title>
          <description>Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of 6-B-Naloxol Plasma Concentration</title>
        <description>T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of 6-B-Naloxol Plasma Concentration</title>
          <description>T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.78" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of 6-B-Naloxol Plasma Concentration</title>
        <description>Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of 6-B-Naloxol Plasma Concentration</title>
          <description>Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" lower_limit="0.50" upper_limit="14.00"/>
                    <measurement group_id="O2" value="1.75" lower_limit="0.50" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of NLLG Plasma Concentration</title>
        <description>AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of NLLG Plasma Concentration</title>
          <description>AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57735.72" spread="24399.37"/>
                    <measurement group_id="O2" value="209514.4" spread="104345.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of NLLG Plasma Concentration</title>
        <description>AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of NLLG Plasma Concentration</title>
          <description>AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57737.49" spread="24400.80"/>
                    <measurement group_id="O2" value="209514.4" spread="104345.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of NLLG Plasma Concentration</title>
        <description>AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of NLLG Plasma Concentration</title>
          <description>AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.13" spread="14.09"/>
                    <measurement group_id="O2" value="20.07" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of NLLG Plasma Concentration</title>
        <description>AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of NLLG Plasma Concentration</title>
          <description>AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62953.71" spread="26257.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of NLLG Plasma Concentration</title>
        <description>Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of NLLG Plasma Concentration</title>
          <description>Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3442.63" spread="1800.17"/>
                    <measurement group_id="O2" value="11372.74" spread="5426.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of NLLG Plasma Concentration</title>
        <description>Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of NLLG Plasma Concentration</title>
          <description>Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of NLLG Plasma Concentration</title>
        <description>T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of NLLG Plasma Concentration</title>
          <description>T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of NLLG Plasma Concentration</title>
        <description>Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of NLLG Plasma Concentration</title>
          <description>Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" lower_limit="0.50" upper_limit="14.00"/>
                    <measurement group_id="O2" value="1.50" lower_limit="0.50" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of NLXG Plasma Concentration</title>
        <description>AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of NLXG Plasma Concentration</title>
          <description>AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78725.81" spread="28285.24"/>
                    <measurement group_id="O2" value="320734.4" spread="113332.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of NLXG Plasma Concentration</title>
        <description>AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of NLXG Plasma Concentration</title>
          <description>AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77976.24" spread="28477.82"/>
                    <measurement group_id="O2" value="320734.4" spread="113332.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of NLXG Plasma Concentration</title>
        <description>AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of NLXG Plasma Concentration</title>
          <description>AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.05"/>
                    <measurement group_id="O2" value="1.86" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of NLXG Plasma Concentration</title>
        <description>AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of NLXG Plasma Concentration</title>
          <description>AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79025.78" spread="28389.19"/>
                    <measurement group_id="O2" value="326907.3" spread="115103.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of NLXG Plasma Concentration</title>
        <description>Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of NLXG Plasma Concentration</title>
          <description>Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11488.62" spread="2493.48"/>
                    <measurement group_id="O2" value="45789.83" spread="10576.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of NLXG Plasma Concentration</title>
        <description>Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of NLXG Plasma Concentration</title>
          <description>Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.03"/>
                    <measurement group_id="O2" value="0.09" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of NLXG Plasma Concentration</title>
        <description>T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of NLXG Plasma Concentration</title>
          <description>T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="1.35"/>
                    <measurement group_id="O2" value="8.40" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of NLXG Plasma Concentration</title>
        <description>Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of NLXG Plasma Concentration</title>
          <description>Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-48hr of Naloxone Plasma Concentration</title>
        <description>AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-48hr of Naloxone Plasma Concentration</title>
          <description>AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.91" spread="122.61"/>
                    <measurement group_id="O2" value="650.42" spread="222.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t of Naloxone Plasma Concentration</title>
        <description>AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t of Naloxone Plasma Concentration</title>
          <description>AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.17" spread="92.95"/>
                    <measurement group_id="O2" value="443.88" spread="252.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC_%Extrap of Naloxone Plasma Concentration</title>
        <description>AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC_%Extrap of Naloxone Plasma Concentration</title>
          <description>AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.82" spread="20.95"/>
                    <measurement group_id="O2" value="44.94" spread="26.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf of Naloxone Plasma Concentration</title>
        <description>AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of Naloxone Plasma Concentration</title>
          <description>AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Naloxone Plasma Concentration</title>
        <description>Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Naloxone Plasma Concentration</title>
          <description>Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.21" spread="24.62"/>
                    <measurement group_id="O2" value="45.10" spread="21.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lambda_z of Naloxone Plasma Concentration</title>
        <description>Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lambda_z of Naloxone Plasma Concentration</title>
          <description>Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 of Naloxone Plasma Concentration</title>
        <description>T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 of Naloxone Plasma Concentration</title>
          <description>T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <population>If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf &lt; 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of Naloxone Plasma Concentration</title>
        <description>Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
        <time_frame>Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OXN Prolonged Release Tablet 5/2.5mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/2.5mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
          <group group_id="O2">
            <title>OXN Prolonged Release Tablet 20/10mg</title>
            <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Naloxone Plasma Concentration</title>
          <description>Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="5.00" upper_limit="14.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events will be recorded from the point at which the Informed Consent is signed until 7(+3) days after the subject leaves the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OXN PR Tablet 5/2.5 mg</title>
          <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
        </group>
        <group group_id="E2">
          <title>OXN PR Tablet 20/10 mg</title>
          <description>The subjects will be randomized to receive either a single dose of OXN prolonged release tablets 5/25mg, 20/10 mg for one time.
OXN PR tablet: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>vomit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Difficult defecation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Imbalance of autonomic nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>dry pharynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Junjiao Ma</name_or_title>
      <organization>Mundipharma (China) Pharmaceutical Co. , Ltd</organization>
      <phone>01065636711</phone>
      <email>Junjiao.Ma@mundipharma.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

